Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 1078-1086

  Cine, Naci ^a   Baykal, Ahmet Tarik ^b   Sunnetci, Deniz ^a   Canturk, Zafer ^a   Serhatli, Muge ^c   Savli, Hakan ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^c Research Institute for Genetic Engineering and Biotechnology   (Turkey)

Author keywords

ApoA1; Breast cancer; HPX; Microarray; MMP 9; NF B; Omic analysis; POTEE

Indexed keywords

APOLIPOPROTEIN A1; HEMOPEXIN; APOA1 PROTEIN, HUMAN; POTE-2GAMMA PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; APOA1 GENE; ARTICLE; BIOMICS; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENOME ANALYSIS; HPX GENE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; POTEE GENE; PRIORITY JOURNAL; PROTEOMICS; TRANCRIPTOMICS; UPREGULATION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ANTIGENS, NEOPLASM; APOLIPOPROTEIN A-I; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HEMOPEXIN; HUMANS; MIDDLE AGED;

EID: 84923068300     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3277     Document Type: Article

References (56)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin D: Globocan 2008: Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, Lyon, pp1027-5614, 2008.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
3. Tuncer M (ed): Significance of Cancer in Turkey, the Burden of Disease and Cancer Control Policies. Cancer Control in Turkey. Vol 74. Onur Press, Health Ministry Publication, Ankara, pp5-9, 2008.
4. Statistical Analyses of National Breast Cancer Registry Program of Turkish Federation of Breast Societies 2008 Executive Summary of the National Cancer Control Programmes: Policies and Managerial Guidelines. World Health Organization, Geneva, 2002.
5. Héry C, Ferlay J, Boniol M and Autier P: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 19: 1187-1194, 2008. (Pubitemid 351796346)
6. Ruder EH1, Dorgan JF, Kranz S, Kris-Etherton PM and Hartman TJ: Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer 8: 334-342, 2008.
7. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC and Henderson BE: Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 169: 1251-1259, 2009.
8. Martin DB and Nelson PS: From genomics to proteomics: techniques and applications in cancer research. Trends Cell Biol 11: S60-S65, 2001.
9. Bhati A, Garg H, Gupta A, Chhabra H, Kumari A and Patel T: Omics of cancer. Asian Pac J Cancer Prev 13: 4229-4233, 2012.
10. Dupont WD and Page DL: Risk factors for breast cancer in women with proliferative disease. N Engl J Med 312: 146-151, 1985. (Pubitemid 15192861)
11. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727, 1996.
12. Bièche I and Lidereau R: Genome-based and transcriptome-based molecular classification of breast cancer. Curr Opin Oncol 23: 93-99, 2011.
13. Marcotte R and Muller WJ: Signal transduction in transgenic mouse models of human breast cancer - implications for human breast cancer. J Mammary Gland Biol Neoplasia 13: 323-335, 2008.
14. D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M and Normanno N: Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 123: 387-396, 2010.
15. Reese DM and Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997. (Pubitemid 27057075)
16. Shen Q and Brown PH: Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8: 45-73, 2003. (Pubitemid 38129950)
17. Hyduke DR, Lewis NE and Palsson BØ: Analysis of omics data with genome-scale models of metabolism. Mol Biosyst 9: 167-174, 2013.
18. Grundy SM and Vega GL: Role of apolipoprotein levels in clinical practice. Arch Intern Med 8: 1579-1582, 1990. (Pubitemid 20240967)
19. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC and Kerensky R: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300, 2003. (Pubitemid 37430562)
20. Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH and Rader DJ: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97: 763-771, 2005. (Pubitemid 41447126)
21. Jahangiri A: High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 17: 156-160, 2010.
22. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY and Pfeiffer RM: Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 15: 1641-1646, 2006. (Pubitemid 44497099)
23. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S and Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5: 4589-4596, 2005. (Pubitemid 41739936)
24. Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW and Friess H: Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205-214, 2007. (Pubitemid 46294796)
25. Takaishi S and Wang TC: Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci 98: 284-293, 2007. (Pubitemid 46195596)
26. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S and Farias-Eisner R: Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 200: 639.e1-639.e5, 2009.
27. Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L and Chahed K: Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep 38: 1637-1643, 2011.
28. Lv GM, Li P, Wang WD, Wang ShK, Chen JF and Gong YL: Lysophosphatidic acid (LPA) and endothelial differentiation gene (Edg) receptors in human pancreatic cancer. J Surg Oncol 104: 685-691, 2011.
29. Panupinthu N, Lee HY and Mills GB: Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 102: 941-946, 2010.
30. Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA and Hazen SL: The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 288: 21237-21252, 2013.
31. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P and Burger D: Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381-2389, 2001. (Pubitemid 32291485)
32. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006. (Pubitemid 43139720)
33. Bendrik C, Robertson J, Gauldie J and Dabrosin C: Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res 68: 3405-3412, 2008.
34. Kato K, Hara A, Kuno T, et al: Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol 131: 340-346, 2005. (Pubitemid 40674618)
35. Groblewska M, Siewko M, Mroczko B and Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 50: 12-19, 2012.
36. Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262, 2002. (Pubitemid 34633925)
37. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM and Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99: 81-92, 1999. (Pubitemid 29468632)
38. Catania JM, Chen G and Parrish AR: Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292: F905-F911, 2007. (Pubitemid 46393417)
39. Labrie M and St-Pierre Y: Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci 70: 3109-3124, 2013.
40. Hayden MS and Ghosh S: Shared principles in NF-KB signaling. Cell 132: 344-362, 2008.
41. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE: Aberrant nuclear factorkappaB/ Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960, 1997. (Pubitemid 28022831)
42. Nakshatri H and Goulet RJ Jr: NF-kappaB and breast cancer. Curr Probl Cancer 26: 282-309, 2002.
43. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-KB activation via the NIK/IKK signalling complex. Oncogene 18: 6013-6020, 1999. (Pubitemid 29535013)
44. Barnes PJ and Karin M: Nuclear factor-KB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997. (Pubitemid 27163860)
45. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV and Dixit VM: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-KB signalling. Nature 430: 694-699, 2004. (Pubitemid 39061687)
46. Tolosano E and Altruda F: Hemopexin: structure, function, and regulation. DNA Cell Biol 21: 297-306, 2002. (Pubitemid 34594543)
47. Kumar S and Bandyopadhyay U: Free heme toxicity and its detoxification systems in human. Toxicol Lett 157: 175-188, 2005. (Pubitemid 40726102)
48. Tolosano E, Fagoonee S, Morello N, Vinchi F and Fiorito V: Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal 12: 305-320, 2010.
49. Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Eaton JW and Balla G: Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol Nutr Food Res 49: 1030-1043, 2005. (Pubitemid 41735563)
50. Murrell TG: Epidemiological and biochemical support for a theory on the cause and prevention of breast cancer. Medical Hypotheses 36: 389-396, 1991.
51. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Barañano DE, Doré S, Poss KD and Snyder SH: Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1: 152-157, 1999. (Pubitemid 129656019)
52. Ho HY, Cheng ML and Chiu DT: Glucose-6-phosphate dehydrogenase - from oxidative stress to cellular functions and degenerative diseases. Redox Rep 12: 109-118, 2007.
53. Bera TK, Zimonjic DB, Popescu NC, Sathyanarayana BK, Kumar V, Lee BK and Pastan I: POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta and prostate cancer. Proc Natl Acad Sci USA 99: 16975-16980, 2002. (Pubitemid 36034083)
54. Bera TK, Huynh N, Maeda H, Sathyanarayana BK, Lee BK and Pastan I: Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. Gene 337: 45-53, 2004. (Pubitemid 38970104)
55. Liu XF, Bera TK, Liu LJ and Pastan I: A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis 14: 1237-1244, 2009.
56. Bera TK, Saint Fleur A, Ha D, Yamada M, Lee Y, Lee B, Hahn Y, Kaufman DS, Pera M and Pastan I: Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. Stem Cells Dev 17: 325-332, 2008. (Pubitemid 351630165)